EN DE
Watch HLscience Co. Ltd for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

HLscience Co. Ltd (239610) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of HLscience Co. Ltd stock KRW 6,079, price KRW 6,490, that is 6.3% below the price, quality 43 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7239610009

HC HLscience Co. Ltd logo Thin data Nov 16, 2026

HLscience Co. Ltd

239610 · KQ

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Fair value 6,079 KRW · Fairly valued 
Quality 43/100 
Revenue last quarter 57% below a year ago. 
Falling price (downtrend) 
Weak Growth (revenue 5y −34.9 %/yr in KRW) 
Loss-making · -106.8% net margin (TTM) 
Negative free cash flow 
Trails peers (3/10) 
Narrow moat 12/100
Thin data 
Estimate
Watch HLscience Co. Ltd for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

39,302 KRW 5,090 KRW Fair Value 6,079 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 5,090 KRW – 39,302 KRW · fair‑value band 4,559 KRW – 7,599 KRW · the 6,490 KRW price screens above the 6,079 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow HLscience Co. in your weekly email

Every Wednesday you see whether HLscience Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

HLscience Co., Ltd. manufactures and sells health functional foods in South Korea.

Show moreShow less

The company offers organic barley grassjuice powder one day, queen's pomegranate jin, Super LuzieA+ Astaxanthin, Dr. Superkhan, HL-JOINT 100 for Joint & Cartilage Premium, Dr. Green Propolis, morosil diet fit, skin master secret, enerlinger vitamin D, PS300 formulated by doctor, Skin Master P-estro, and Dr. Prebiotics Plus.

It also provides CDMO, contract development organization and contract research organization, contract manufacturing organization, quality assurance system, and funding services.

Its products are used for antioxidant/skin health/immune function, female menopausal health/skin moisturizing/UV care, liver health, cartilage and joint health/bone health, body fat reduction/energy metabolism, brain health/blood circulation improvement, and gut health applications.

The company was founded in 2000 and is headquartered in Hwaseong-si, South Korea.

Stock analysis

HLscience Co. Ltd (239610) currently trades at 6,490 KRW, while our estimate is 6,079 KRW, so the stock looks roughly fairly valued today (gap 6.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 4,559 KRW (bear) to 7,599 KRW (bull), the price of 6,490 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

HLscience Co. Ltd reported revenue of 16.7B KRW in FY2025 versus 104B KRW in FY2021, a compound −36.7%/yr. Reported net income was −11.9B KRW in FY2025.

Key figures

Market cap 33.1B KRW (≈ $24.9M) Micro · P/S ratio 2.85 · EPS (TTM) −2,190 KRW · Net margin −107% · Return on equity −13.4% · Return on assets (EBIT) −3.1% (5-year average) · Operating margin −112% · Revenue (TTM) 10.4B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 29% below its 52-week high and 28% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −6%, 239610 screens cheaper than that median.

Fair Value

Bear 4,559 KRW Fair Value 6,079 KRW Bull 7,599 KRW
Price 6,490 KRW · Downside -6.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 43/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 32
Are margins and returns getting better?
Cashflow 2
Do the profits arrive as real cash?
Financial strength 76
Debt, balance sheet and risk of trouble
Investment 98
Does it invest with discipline instead of growing at any price?
Low Volatility 62
How calm the share price moves, does not count
Price momentum 30
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 23
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−5.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−31.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−34.9%
Start year 2020 (pandemic). Over 10 years: −3.4% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
16.5% (2020) → −66.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 239610, get fair value alerts →

Compare HLscience Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks

Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 43 · Below median
Fair Value upside −6.3% · Above median
Profitability
Return on assets −14.0% · Bottom 25%
Net margin (12 months) −106.8% · Bottom 25%
Operating margin (12 months) −111.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −57.1% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.40× · Cheapest 25%
P/S (12 months) 3.17× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)25 · sector 20
FUTURE (revenue growth)0 · sector 29
PAST (return on equity)0 · sector 26
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 33

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $85.57 $113.53 +33% vs 239610
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥46.88 ¥52.43 +12% vs 239610
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,900 ₹1,983 +4% vs 239610
Haleon plc HLN $9.08 $8.47 −7% vs 239610
Merck KGaA MRK €148.40 €108.83 −27% vs 239610
Galderma Group GALD CHF 184.70 CHF 112.46 −39% vs 239610
Takeda Pharmaceutical Company TAK $21.27 $11.23 −47% vs 239610
Sandoz Group SDZ CHF 81.24 CHF 41.06 −49% vs 239610
Teva Pharmaceutical Industries Limited TEVA $42.23 $20.74 −51% vs 239610
Divi's Laboratories Limited DIVISLAB ₹11,178 ₹1,567 −86% vs 239610

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

HLscience Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "HLscience Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/239610

Frequently asked questions

Is HLscience Co. Ltd (239610) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 6,079 KRW versus a price of 6,490 KRW, about 6% lower (fairly valued).
What is the fair value of 239610?
Our estimate for HLscience Co. Ltd is 6,079 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 6,490 KRW.
What is the quality score of 239610?
HLscience Co. Ltd has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for HLscience Co. Ltd (239610)?
We do not set a price target; the yardstick is our estimate of 6,079 KRW (as of Nov 16, 2026). Cautious scenario 4,559 KRW, optimistic scenario 7,599 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the HLscience Co. Ltd stock forecast for 2026?
Our estimate puts fair value at 6,079 KRW, about 6% lower versus a price of 6,490 KRW (fairly valued). Cautious scenario 4,559 KRW, optimistic scenario 7,599 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of HLscience Co. Ltd (239610)?
HLscience Co. Ltd reported trailing-twelve-month revenue of about 10.4B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of HLscience Co. Ltd (239610)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For HLscience Co. Ltd it is 6,079 KRW per share (as of Nov 16, 2026), against a price of 6,490 KRW.
Is HLscience Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 239610 trades above its calculated fair value: price 6,490 KRW, fair value 6,079 KRW, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 239610?
No. The price is what the market pays today (6,490 KRW); the fair value is what the company's own numbers justify (6,079 KRW). For HLscience Co. Ltd the two are 411.03 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is HLscience Co. Ltd worth?
The market values HLscience Co. Ltd at about 33.1B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 6,490 KRW; our models calculate a fair value of 6,079 KRW per share.
What do the bullish and bearish scenarios say about 239610?
Our models span a range for HLscience Co. Ltd: cautious scenario 4,559 KRW, base 6,079 KRW, optimistic 7,599 KRW per share (as of Nov 16, 2026, price 6,490 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of HLscience Co. Ltd (239610)?
Balance-sheet figures for HLscience Co. Ltd (as of Nov 16, 2026): return on equity −13.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.
How far is 239610 from its 52-week high?
HLscience Co. Ltd trades at 6,490 KRW, about 29% below its 52-week high of 9,180 KRW and 28% above the low of 5,090 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 6,079 KRW is for.
Which stocks are comparable to HLscience Co. Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is HLscience Co. Ltd stock attractive at the current price?
The data as of Nov 16, 2026: price 6,490 KRW, calculated fair value 6,079 KRW (−6%), Quality Score 43/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. HLscience Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of HLscience Co. Ltd (239610)?
The closing price on Nov 19, 2026 was 6,490 KRW. Our estimate is 6,079 KRW, about 6% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with HLscience Co. Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of HLscience Co. Ltd

How large is the market capitalisation of HLscience Co. Ltd (239610)?
The market capitalisation of HLscience Co. Ltd is 33.1B KRW (≈ $24.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of HLscience Co. Ltd (239610)?
The price-to-sales ratio of HLscience Co. Ltd is 2.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of HLscience Co. Ltd (239610)?
Earnings per share at HLscience Co. Ltd are −2,190 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of HLscience Co. Ltd (239610)?
The net margin of HLscience Co. Ltd is −107% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of HLscience Co. Ltd (239610)?
The return on equity (ROE) of HLscience Co. Ltd is −13.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of HLscience Co. Ltd (239610)?
On an EBIT basis the return on assets of HLscience Co. Ltd is −3.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of HLscience Co. Ltd (239610)?
The operating margin of HLscience Co. Ltd is −112% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at HLscience Co. Ltd (239610)?
Revenue at HLscience Co. Ltd is down 57.1% versus a year earlier (3y avg −31.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at HLscience Co. Ltd (239610)?
Earnings per share at HLscience Co. Ltd are down 94.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does HLscience Co. Ltd (239610) generate?
The free cash flow of HLscience Co. Ltd is −7.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch HLscience Co. Ltd in the live analysis

One click puts HLscience Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.